J B CHEMICALS AND PHARMA
JBCHEPHARM · NSE · inactive
2,408.90
-97.10 (-3.87%)
as of 16 Jul 2026 close
Open
2,506.00
High
2,525.50
Low
2,380.00
Prev close
2,506.00
52w high
2,525.50
16 Jul 2026
52w low
1,638.50
26 Sept 2025
VWAP
2,418.56
Delivery %
66.8%
of volume
Volume 47.79 L · turnover ₹1155.88 Cr · NSE bhavcopy (official close), adjusted for splits/bonuses · history since 02 Feb 1995
- Series
- EQ
- F&O
- No
- Status
- Inactive since 17 Jul 2026
Source: NSE equity master · as of 16 Jul 2026
Market cap
—
P/B
—
ROE (TTM)
16.7%
ROCE 22.5%
Debt / equity
0.00
P/E (TTM)
—
P/S (TTM)
—
Revenue TTM
₹3,890 cr
Net profit TTM
₹674 cr
Net margin TTM
17.3%
OPM 26.4%
EV / EBITDA
—
Interest cover
197.7×
Revenue growth
-7.2%
latest quarter YoY
Profit growth
-35.6%
latest quarter YoY
Dividend yield
—
₹22 / share · payout —
Standalone · last four quarters to 2026-03-31 · balance sheet 2026-03-31 · tap a tile for the formula
Daily · NSE EOD
Bulk & block deals · NSE daily reports
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.34 |
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.00 |
| 27 Mar 2025 | bulk | KOTAK MAHINDRA MUTUAL FUND | BUY | 12.31 L | 1,625.00 |
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.00 |
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.01 |
| 18 Sept 2020 | bulk | THE VANGUARD GROUP INC A/C VANGUARD EMERG. MKTS STOCK INDEXFD A SERIES OF V I E I F | BUY | 7.07 L | 1,121.89 |
| 02 Nov 2017 | bulk | ASHISH DHAWAN | SELL | 4.72 L | 289.54 |
| 01 Nov 2017 | bulk | ASHISH DHAWAN | SELL | 19.52 L | 288.12 |
Quarterly results · Standalone · latest 31 Mar 2026
filed 11 May 2026, 09:39 pm IST| ₹ crore | Dec 24* | Mar 25* | Jun 25* | Sept 25* | Dec 25* | Mar 26* |
|---|---|---|---|---|---|---|
| Revenue | 2,822 | 901 | 1,040 | 1,023 | 991 | 836 |
| Other income | 21 | 14 | 14 | 14 | 17 | 10 |
| Total expenses | 2,165 | 716 | 789 | 768 | 767 | 691 |
| Operating margin | 27.9% | 25.6% | 28.2% | 29.2% | 27.2% | 20.1% |
| Finance costs | 8 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 122 | 44 | 41 | 43 | 44 | 49 |
| Profit before tax | 678 | 199 | 265 | 268 | 241 | 128 |
| Tax | 175 | 49 | 67 | 68 | 62 | 32 |
| Net profit | 503 | 150 | 198 | 200 | 179 | 97 |
| Net margin | 17.8% | 16.6% | 19.0% | 19.6% | 18.1% | 11.5% |
| EPS (₹) | 32.38 | 9.63 | 12.70 | 12.82 | 11.45 | 6.05 |
Annual results · 12-month figures as filed
| ₹ crore | FY25* | FY26* |
|---|---|---|
| Revenue | 3,723 | 3,890 |
| Other income | 35 | 55 |
| Total expenses | 2,881 | 3,015 |
| Operating margin | 27.3% | 26.4% |
| Finance costs | 9 | 5 |
| Depreciation | 166 | 177 |
| Profit before tax | 877 | 903 |
| Tax | 225 | 229 |
| Net profit | 653 | 674 |
| Net margin | 17.5% | 17.3% |
| EPS (₹) | 42.00 | 42.91 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison